Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc R&D Day (Virtual) Transcript

Nov 30, 2021 / 04:00PM GMT
Release Date Price: $86.24 (-2.61%)
Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

Welcome, everybody. I'm Hank Fuchs, and this is BioMarin's R&D Day 2021. Since we last saw you in 2019, it's been a busy year. We've been noses down, and there have been a lot of deep technical and infrastructural developments that have occurred at BioMarin to support our pipeline pivot that I want to tell you about. We're thrilled to share some of the early outputs of that today.

The agenda is here, but part of my introduction will walk you through the key elements of each of these presentations to highlight some of the most important things you're going to hear.

Let's dive in. First, I want to remind you all of our scientific strategy often referred to as the core 4. Then I want to brief you on the outputs and next steps of our pipeline pivot. You've heard us talk a lot about it, and today, you'll get a look under the hood.

I want to provide a little bit of a spoiler on some of the important things you'll hear today from each of our individual speakers. And finally, I'll then

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot